Can we use viral kinetic models to individualize treatment?
IAME, UMR 1137, INSERM, Paris, France; IAME, UMR 1137, Univ Paris Diderot, Paris, France.
Jeremie
J
Guedj
Thi Huyen Tram
TH
Nguyen
D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008954:Models, Biological; D057285:Precision Medicine / Q000379:methods*; D012367:RNA, Viral / Q000187:drug effects; D000077385:Silybin; D012838:Silymarin / Q000494:pharmacology
D012367:RNA, Viral; D012838:Silymarin; D000077385:Silybin